2022
NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma
Jain D, Nambirajan A, Chen G, Geisinger K, Hiroshima K, Layfield L, Minami Y, Moreira A, Motoi N, Papotti M, Rekhtman N, Russell P, Prince S, Schmitt F, Yatabe Y, Eppenberger-Castori S, Bubendorf L, Beasley M, Berezowska S, Borczuk A, Brambilla E, Chou T, Chung J, Cooper W, Dacic S, Chan Y, Hirsch F, Hwang D, Joubert P, Kerr K, Lantuejoul S, Lin D, Lopez-Rios F, Matsubara D, Mino-Kenudson M, Nicholson A, Poleri C, Roden A, Schalper K, Sholl L, Thunnissen E, Travis W, Tsao M, Wistuba I, Chen G. NSCLC Subtyping in Conventional Cytology: Results of the International Association for the Study of Lung Cancer Cytology Working Group Survey to Determine Specific Cytomorphologic Criteria for Adenocarcinoma and Squamous Cell Carcinoma. Journal Of Thoracic Oncology 2022, 17: 793-805. PMID: 35331963, DOI: 10.1016/j.jtho.2022.02.013.Peer-Reviewed Original Research
2016
EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma
Toki MI, Carvajal-Hausdorf DE, Altan M, McLaughlin J, Henick B, Schalper KA, Syrigos KN, Rimm DL. EGFR-GRB2 Protein Colocalization Is a Prognostic Factor Unrelated to Overall EGFR Expression or EGFR Mutation in Lung Adenocarcinoma. Journal Of Thoracic Oncology 2016, 11: 1901-1911. PMID: 27449805, PMCID: PMC5075503, DOI: 10.1016/j.jtho.2016.06.025.Peer-Reviewed Original ResearchConceptsEGFR pathway activationSeries of patientsLung adenocarcinomaMutation statusEGFR expressionPathway activationProximity ligation assayKRAS wild-type tumorsEGFR-mutant patientsKRAS-mutant casesCohort of patientsWild-type tumorsInteraction of EGFREGFR expression levelsEGFR protein expressionMAPK/ERK pathwayGrowth factor receptorActive EGFRPrognostic factorsDifferent mutation statusPatient groupPrognostic valueLonger survivalEGFR mutationsPrognostic marker
2014
Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing
Viray H, Coulter M, Li K, Lane K, Madan A, Mitchell K, Schalper K, Hoyt C, Rimm DL. Automated Objective Determination of Percentage of Malignant Nuclei for Mutation Testing. Applied Immunohistochemistry & Molecular Morphology 2014, 22: 363-371. PMID: 24162261, PMCID: PMC3999345, DOI: 10.1097/pai.0b013e318299a1f6.Peer-Reviewed Original ResearchConceptsCriterion standardMalignant cellsMalignant nucleiCompanion diagnostic testsTumor cell percentageMutation testingEosin-stained tissuesCell percentageInForm softwareHistologic specimensTumor tissueColon adenocarcinomaTumor cellsDiagnostic testsPotential future toolDNA mutation testingTissue sectionsContinuous variablesFurther validationPathologist estimationAnalytic sensitivityVariant resultsDNA mutationsBenign nucleiTissueMutacin del gen BRAF en pacientes con cnceres de colon y recto con KRAS no mutado
Roa I, Game A, Bizama C, Schalper K. Mutacin del gen BRAF en pacientes con cnceres de colon y recto con KRAS no mutado. Revista Medica De Chile 2014, 142: 55-60. PMID: 24861115, DOI: 10.4067/s0034-98872014000100009.Peer-Reviewed Original ResearchConceptsBRAF V600E mutationV600E mutationColorectal cancerPrimary tumorKRAS mutationsIndependent prognostic factorBRAF gene mutationRestriction fragment length polymorphismColorectal cancer samplesGrowth factor pathwaysLiver metastasesPrognostic factorsMetastatic adenocarcinomaTumor locationBRAF geneFactor pathwayMonoclonal antibodiesCancer samplesMutation casesGene mutationsTissue samplesPatientsDirect sequencingMetastasisColon
2013
Expresin y amplificacin del gen HER2 en el cncer gstrico avanzado
Roa I, Slater J, Carvajal D, Schalper K, de Toro G, Ares R, Game A, Len J, de Aretxabala X. Expresin y amplificacin del gen HER2 en el cncer gstrico avanzado. Revista Medica De Chile 2013, 141: 1411-1419. PMID: 24718467, DOI: 10.4067/s0034-98872013001100007.Peer-Reviewed Original ResearchMutacin del gen KRAS en el cncer de colon y recto
Roa I, Snchez T, Majlis A, Schalper K. Mutacin del gen KRAS en el cncer de colon y recto. Revista Medica De Chile 2013, 141: 1166-1172. PMID: 24522420, DOI: 10.4067/s0034-98872013000900009.Peer-Reviewed Original ResearchConceptsKRAS mutationsPrimary tumorColorectal cancer tissue samplesTissue samplesColo-rectal cancerCancer tissue samplesColorectal cancerMetastatic tumorsTumor locationColorectal carcinogenesisG12C mutationCodon 13KRAS oncogeneCodon 12Tumor samplesTumorsExtraction sitesDirect sequencingCancerDistribution of mutationsMutationsPoint mutationsMetastasisRectumColonSarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1)
Velcheti V, Rimm DL, Schalper KA. Sarcomatoid Lung Carcinomas Show High Levels of Programmed Death Ligand-1 (PD-L1). Journal Of Thoracic Oncology 2013, 8: 803-805. PMID: 23676558, PMCID: PMC3703468, DOI: 10.1097/jto.0b013e318292be18.Peer-Reviewed Original ResearchConceptsDeath ligand 1Sarcomatoid carcinomaCell lung carcinomaLung carcinomaPD-L1PD-1/PD-L1 axisPD-1/PD-L1 pathwayProgrammed Death Ligand 1PD-L1 protein expressionEffector immune responsesPD-L1 axisPD-L1 pathwayLung sarcomatoid carcinomaLung cancer cohortSarcomatoid lung carcinomasLigand 1Mouse monoclonal antibodyDeath-1Lymphocytic infiltrationRare subtypeSuch therapyCancer cohortT cellsCarcinomaTumor types